Prostate Cancer - Results from #23760

GU Cancers Symposium 2013 - Session Highlights: Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD February 26, 2013

GU Cancers Symposium 2013 - Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD, et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Lower risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists, by Peter Albertsen, MD, et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials, by E. David Crawford, MD et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Galeterone, abiraterone, orteronel and ketoconazole exhibit differential inhibitory effects on CYP17 and steroidogenesis, by Douglas B. Jacoby and Martin Williams - Poster February 26, 2013

GU Cancers Symposium 2013 - A randomized, phase II, open-label study of sipuleucel-t with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Poster February 26, 2013

Prostate cancer brachytherapy: Guidelines overview - Abstract February 26, 2013

Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy - Abstract February 26, 2013

Bone targeted therapies in metastatic castration-resistant prostate cancer - Abstract February 26, 2013

Re-implantation of suboptimal prostate seed implantation: Technique with intraoperative treatment planning - Abstract February 26, 2013

GU Cancers Symposium 2013 - Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis, by Douglas B. Jacoby, et al. - Session Highlights February 26, 2013

GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer - Session Highlights February 26, 2013

GU Cancers Symposium 2013 - Effect of PSA-TRICOM, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa, by James L. Gulley, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study, by Robert van Soest, et al. - Session Highlights February 25, 2013

From "magic bullets" to specific cancer immunotherapy - Abstract February 25, 2013

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer - Abstract February 25, 2013

Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy - Abstract February 25, 2013

Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning - Abstract February 25, 2013

'Living under assault': Men making sense of cancer - Abstract February 25, 2013

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer - Abstract February 25, 2013

Page 1189 of 1436